Blue Owl Capital Holdings LP Acquires New Shares in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Blue Owl Capital Holdings LP bought a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 667,594 shares of the company's stock, valued at approximately $4,974,000. EyePoint Pharmaceuticals makes up 1.2% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 19th largest holding. Blue Owl Capital Holdings LP owned about 0.98% of EyePoint Pharmaceuticals at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Summit Investment Advisors Inc. lifted its position in EyePoint Pharmaceuticals by 39.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock valued at $51,000 after purchasing an additional 1,940 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in EyePoint Pharmaceuticals during the fourth quarter valued at $59,000. AlphaQuest LLC lifted its position in EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock valued at $73,000 after purchasing an additional 9,670 shares in the last quarter. Raymond James Financial Inc. purchased a new position in EyePoint Pharmaceuticals during the fourth quarter valued at $76,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in EyePoint Pharmaceuticals by 40.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company's stock valued at $108,000 after purchasing an additional 4,179 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Citigroup assumed coverage on EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. StockNews.com upgraded EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. HC Wainwright restated a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Finally, Chardan Capital restated a "buy" rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.63.

EyePoint Pharmaceuticals Trading Down 2.4 %

Shares of EYPT stock traded down $0.16 on Tuesday, reaching $6.62. The company's stock had a trading volume of 134,292 shares, compared to its average volume of 885,926. The company has a market capitalization of $454.99 million, a price-to-earnings ratio of -3.30 and a beta of 1.39. The stock's fifty day simple moving average is $5.93 and its 200-day simple moving average is $7.73. EyePoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $21.26.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). The company had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Equities research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current year.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.